Latest Carpuject Stories
DUBLIN, March 12, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lhnsht/injectable_drug) has announced the addition of the "Injectable Drug Delivery to 2018 Drugs, Devices, Targets, Therapeutics and Forecasts" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the...
OTTAWA, March 8, 2013 /CNW/ - Health Canada is informing Canadians and Canadian health care practitioners that Hospira Inc., a drug and medical device manufacturer, is voluntarily stopping all new sales of its intravenous infusion pumps while it addresses issues in its quality management system. Health Canada is monitoring Hospira's actions to resolve any quality, safety and effectiveness issues related to its infusion pumps sold in Canada and will take corrective action...
LAKE FOREST, Ill., and PETACH TIKVA, Israel, Jan. 22, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and Q Core Medical, Ltd., an innovation leader in infusion delivery systems, today announced that the companies have entered into a distribution agreement for the Q Core Sapphire(TM) multi-therapy infusion system. Through the arrangement, Hospira will have exclusive rights to market and distribute Sapphire...
YORK, Pa., Dec. 19, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today announced that another U.S. based pharmaceutical company has commenced stability and evaluation studies of the Unifill syringe for use with multiple injectable drugs. The target drugs, which include both pipeline drugs as well as commercially approved drugs that will benefit from lifecycle extension, are high-value therapeutics for chronic diseases and require...
YORK, Pa., Nov. 8, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that its Precision-Therapy(TM) platform of bolus injection systems has been selected by a global pharmaceutical company to enter the next stage of collaboration as its preferred choice for long-duration subcutaneous drug delivery. Unilife has been advised that the global pharmaceutical company (the "Customer") is targeting more than five pipeline...
LAKE FOREST, Ill., Aug. 29, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced an agreement for Hospira to acquire an active pharmaceutical ingredient (API) manufacturing facility, together with an associated research and development (R&D) facility, from Orchid Chemicals & Pharmaceuticals Ltd. (BSE: 524372, NSE: ORCHIDCHEM), a leading Indian pharmaceuticals company, for approximately...
LAKE FOREST, Ill., Aug. 9, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today the U.S. re-launch of oxaliplatin injection, Hospira's generic version of Sanofi's chemotherapy medication Eloxatin(®). Sales of Eloxatin last year in the United States were approximately $1.5 billion. "We're excited to once again be able to provide this critical oncology drug to our patients and customers," said...
LAKE FOREST, Ill., June 29, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Hospira and Lancaster General Hospital have been selected as the 2012 co-recipients of the Association for the Advancement of Medical Instrumentation (AAMI) Foundation/Institute for Technology in Health Care Clinical Application Award. Given annually to an individual or group that has applied innovative clinical...
TAINAN, Taiwan, June 29, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that it will invest NT$1.13 billion (approximately US$37.6 million) in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company's premise at the Tainan Science Park. ScinoPharm, a global leader in supplying oncological APIs for injectable products, currently has the most number of oncological APIs for the generic...
YORK, Pa., June 18, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced the signing of a seven-year commercial supply contract with a pharmaceutical company for the Unifill® ready-to-fill (prefilled) syringe. Target Drug and MarketThis supply contract for the Unifill syringe relates to the planned launch of a generic equivalent of an approved auto-immune therapy that is currently available in a standard...
